C4 Therapeutics: $11 Price Target from Lake Street Highlights Triple Strategy in Multiple Myeloma
Reading Time: 3 minutes
C4 Therapeutics utilizes targeted protein degradation for cancer treatment and advances the clinical development of the lead candidate Cemsidomide. A recent analyst comment from Lake Street sets a price target of $11 and refers to the company's three-pronged development strategy. Through combination therapies, management specifically aims for deep and lasting remissions in multiple myeloma. Strategic Focus on Targeted Protein Degradation The business model of C4 Therapeutics (CCCC) is based on developing novel therapeutics that utilize...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
